Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raises the price target from $70 to $95.
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raises the price target from $70 to $95.